ICER’s Latest: Draft Evidence Report on New ALS Treatments

On June 14, 2022, ICER released its draft evidence report, “AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis.” This is the first step in ICER's review process. A final evidence report is expected to be released in mid-September. Background on ALS...

FTC Investigating Pharmacy Benefit Managers for Practices Impacting Patient Access

Earlier this month, the Federal Trade Commission (FTC) announced that it had launched a new inquiry into business practices of pharmacy benefit managers (PBMs). Specifically, the the five-member commission said that it would "scrutinize the impact of vertically...

New Study: FDA consistently approves cancer treatments faster than its counterparts in Europe

Over the past decade, the Food and Drug Administration (FDA) has significantly outpaced the European Medicines Agency (EMA) in approving new cancer treatments. This is according to a recent study published in JAMA Network Open. The study included a cross-sectional...

 Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.

Get Updates in Your Inbox

Sign Up.  Stay Informed.

The Conversation